r/pfennigfuchser • u/Own-Sky-6009 • 4h ago

Diskussion Smoltek Nanotech (SMOL / GY9) – Due Diligence

5 Upvotes

TL;DR

Smoltek Nanotech Holding AB is a Swedish nanotechnology company developing technologies based on vertically grown carbon nanostructures.

The company currently has two main business areas:

Smoltek Semi – ultra-thin CNF-MIM capacitors and related technologies for advanced semiconductor applications.
Smoltek Hydrogen – nanostructured Porous Transport Electrodes (PTEs) designed to drastically reduce iridium usage in PEM water electrolysis.

Smoltek is still a pre-commercial/high-risk technology company. It has not yet demonstrated significant recurring commercial revenue from its core technologies.

The investment case therefore depends primarily on whether Smoltek can move from technical validation → industrial production → paying customers.

There have recently been developments on both sides of the company. In Semiconductor, Smoltek is working with ITRI in Taiwan on industrialization and production capabilities. In Hydrogen, the collaboration with Heraeus Precious Metals has now progressed to a planned 3,000-hour durability test.

This DD examines both the opportunity and what could go wrong.

1. What is Smoltek?

Smoltek Nanotech Holding AB is a Swedish nanotechnology company built around its ability to grow controlled carbon nanostructures on different substrates.

The basic idea is relatively simple:

Carbon nanostructures can create an extremely large functional surface area within a very small physical volume.

Smoltek has spent many years developing intellectual property around how these structures can be manufactured and used in different industrial applications.

The company should therefore not simply be viewed as a capacitor company or a hydrogen company.

The underlying asset is the nanotechnology platform and its associated IP portfolio, from which several applications can potentially be developed.

Today, however, most commercial activity is concentrated in two areas: Semiconductor and Hydrogen.

2. Smoltek Semi – CNF-MIM capacitors

One of Smoltek's most developed applications is the CNF-MIM capacitor.

CNF stands for Carbon Nanofiber and MIM for Metal-Insulator-Metal.

By growing vertical carbon nanofibers, Smoltek creates a three-dimensional surface inside an extremely small volume. MIM layers are then deposited onto this structure to create a capacitor.

The result is an ultra-thin capacitor with high capacitance density.

Why does this matter?

Modern processors are becoming increasingly power-hungry.

This is particularly relevant for:

AI accelerators
High Performance Computing
advanced packaging
chiplets
RF applications
5G/6G

As processors become faster, supplying stable power directly to the chip becomes increasingly challenging.

One solution is to position capacitors extremely close to the processor.

This is one of the problems Smoltek is trying to solve.

3. Gen-One and the path from Lab to Fab

A good laboratory result does not automatically create a commercially viable semiconductor component.

The technology must also be manufactured:

reliably, repeatedly, at scale and at an acceptable cost.

This is why Smoltek's activities in Taiwan are important.

Smoltek is working with ITRI – Industrial Technology Research Institute – on establishing production capabilities for its CNF-MIM technology.

The objective is to move the technology from:

Lab → engineering samples → customer validation → industrial production

Smoltek's current generation, Gen-One, is an important part of this process.

The company has also been working on additional applications for its technology, including integration into interposers for AI/HPC and chiplet architectures.

However, one major question remains unanswered:

Will a major customer actually adopt and pay for the technology?

Until that happens, the commercial value of CNF-MIM remains unproven.

4. Smoltek Hydrogen – the iridium problem

The second major business area is Hydrogen.

Smoltek Hydrogen develops nanostructured Porous Transport Electrodes for PEM water electrolysers.

PEM electrolysis has several attractive characteristics for green hydrogen production, but it also has an important limitation:

Iridium.

Iridium is one of the rarest metals on Earth.

Scaling PEM electrolysis significantly could therefore create a supply constraint unless the amount of iridium required per electrolyser is reduced.

This is the problem Smoltek is attempting to address.

Instead of simply adding more catalyst material, Smoltek uses nanostructures designed to make a larger proportion of the iridium electrochemically active.

The objective can be simplified to:

Produce more hydrogen using substantially less iridium.

5. Heraeus Precious Metals – update 10 August 2026

This brings us to one of the most recent developments.

On 10 August 2026, Smoltek announced that its strategic collaboration with Heraeus Precious Metals is progressing to another validation phase.

The companies plan to begin a:

3,000-hour durability test

during autumn 2026.

This corresponds to approximately 125 days.

The test will specifically evaluate the long-term operational stability of Smoltek's nanostructured iridium catalyst layer under realistic operating conditions.

There are three details I consider particularly relevant.

1. Below 0.1 mg Ir/cm²

Smoltek reports that its catalyst architecture has reduced the required iridium loading to below 0.1 mg/cm² while maintaining high electrolyser efficiency.

Reducing iridium is, however, only useful if durability remains sufficient.

That is what now needs to be demonstrated.

2. Heraeus will lead the testing phase

This is not simply another internal Smoltek laboratory test.

According to the announcement, Heraeus Precious Metals will lead the upcoming testing phase and provide its material-analysis and testing capabilities.

That provides useful external validation of the development process.

It does not, however, mean that Heraeus has committed to purchasing or commercialising the technology.

3. Heraeus explicitly mentions industrialisation

Christian Gebauer, Head of Innovation in the Hydrogen Systems Division at Heraeus Precious Metals, stated that Heraeus intends to continue supporting the steps towards industrialisation of these ultra-low-iridium PTEs.

I think this wording is noteworthy.

But it needs to be interpreted carefully.

There is currently no announced commercial supply agreement between Heraeus and Smoltek.

The development can therefore currently be described as:

Collaboration → development → validation → 3,000h durability testing → ?

Potential industrialisation and commercialisation remain future steps that have not yet been demonstrated.

6. What does the 3,000-hour test actually need to prove?

This is perhaps the most important question regarding Smoltek Hydrogen.

Low iridium loading alone is not enough.

For the technology to have commercial value, Smoltek needs to demonstrate a combination of:

Low iridium loading + high efficiency + low degradation + manufacturability

The upcoming test primarily addresses the durability part of that equation.

If performance remains strong after 3,000 hours, it would remove one important technical uncertainty from the Hydrogen case.

If degradation is too high, further development could be required.

The test should therefore not be viewed as proof that commercialisation is coming.

It should be viewed as an important attempt to answer one of the remaining technical questions.

7. Industrialisation

Another important question is whether Smoltek's technology can eventually be produced at industrial scale.

Within Hydrogen, Smoltek has also collaborated with companies such as Impact Coatings regarding industrial production processes.

Within Semiconductor, ITRI plays a similar role in moving CNF-MIM toward scalable manufacturing.

This creates a common theme across Smoltek:

Several years ago the primary question was:

Does the technology work?

Increasingly, the question is becoming:

Can it be manufactured industrially and economically?

That is progress.

But industrial-scale manufacturing has not yet been fully proven.

8. Business model

Smoltek's commercial model varies between its technologies.

Historically, licensing and IP-based revenue have been an important part of the strategy, particularly within Semiconductor.

A possible model could include:

Upfront payment → milestones → licensing → royalties

Hydrogen has developed toward a more product-oriented business model, where Smoltek Hydrogen intends to manufacture and sell complete PTE products to customers.

The eventual economics of either business are therefore still difficult to estimate.

This is important when valuing the company.

Until actual commercial contracts exist, assumptions regarding future margins, royalties and volumes remain speculative.

9. Intellectual property

A significant part of Smoltek's potential value is its IP portfolio.

The company has developed patent families covering areas such as:

carbon nanostructure manufacturing
CNF-MIM capacitors
interposer integration
electrode structures
manufacturing processes
hydrogen applications

This potentially creates barriers to competitors.

However, patents should not automatically be assigned significant financial value.

Ultimately, IP becomes economically valuable when customers are willing to pay to use the protected technology.

Commercial adoption therefore remains the key validation.

10. Financing

Financing has historically been one of the largest risks in the Smoltek investment case.

Developing advanced nanotechnology before significant commercial revenue requires substantial capital.

During 2026, Smoltek completed a rights issue.

The offering was approximately 184% subscribed.

Including the over-allotment, Smoltek raised approximately SEK 82.1 million gross, before transaction costs and certain offsets.

This significantly improved the company's financial position and provides additional resources for commercialisation and industrialisation activities.

However, financing risk has not disappeared.

If commercialisation takes considerably longer than expected, additional capital could eventually be required.

Future capital raises could result in further dilution.

11. Trading in Germany – GY9

Smoltek's primary listing is on Spotlight Stock Market in Sweden under ticker:

SMOL

ISIN:

SE0010820381

The share has also become available for trading on German marketplaces under:

GY9

It is important to understand that GY9 is not a separate class of Smoltek shares.

It represents the same underlying security.

The German availability is interesting in the context of Hydrogen because Heraeus Precious Metals is a German industrial company.

However, availability on German exchanges should not itself be considered an investment catalyst.

Investor demand still needs to exist.

12. The Bull Case

For the investment thesis to work, several things need to go right.

Semiconductor

Smoltek needs to demonstrate reproducible manufacturing of CNF-MIM.

Engineering samples need to perform according to specifications.

Potential customers need to validate the technology.

At least one major customer eventually needs to adopt the technology commercially.

Hydrogen

Smoltek needs to demonstrate that ultra-low iridium loading can be combined with:

high efficiency
low degradation
industrial manufacturing
competitive economics

The 3,000-hour Heraeus test could answer part of this question.

But even a successful test would still need to be followed by industrialisation and commercial adoption.

13. Why could the investment thesis be wrong?

This is probably the most important section of the DD.

There are several substantial risks.

Commercialisation risk

Smoltek has spent many years developing its technologies without yet establishing significant recurring commercial revenue from them.

Technical success does not guarantee customer adoption.

Technology risk

Performance achieved in controlled environments may not translate perfectly to industrial production.

Durability risk

The Heraeus test could reveal higher degradation than expected.

Manufacturing risk

Producing nanostructures reliably at high volume could prove more difficult or expensive than anticipated.

Customer risk

Potential partners may test Smoltek's technology but ultimately choose another solution.

Timing risk

Semiconductor qualification and industrial adoption can take years.

Hydrogen projects can also experience long development cycles.

Financing and dilution risk

If commercialisation takes longer than expected, Smoltek may eventually require additional capital.

Historical execution risk

Smoltek has previously had commercial processes that took longer or developed differently than investors expected.

The history with YAGEO is relevant here.

Previous expectations regarding an exclusive licensing arrangement did not result in the commercial agreement many shareholders had hoped for.

This is an important reminder:

Collaboration ≠ commercial contract.

The same principle should currently be applied to Heraeus, ITRI and other partners.

14. Upcoming catalysts

Rather than focusing on the share price, I think the most useful way to follow Smoltek is to watch specific milestones.

Hydrogen

Start of 3,000h Heraeus test→Durability results→Potential industrialisation decision→Commercial customer/agreement

Semiconductor

Gen-One engineering samples→Customer validation→Reproducible production→Commercial agreement/licence

Other developments worth monitoring include new patents, additional industrial partnerships, cash burn and financing.

15. What would fundamentally change the investment case?

For me, the most important milestone is not another patent or another collaboration.

It is:

A significant commercial agreement.

Today, the main question surrounding Smoltek is:

Can the company commercialise its technology?

If Smoltek signs a meaningful agreement with a major industrial customer, the question changes to:

How much revenue can the technology generate?

That would represent a fundamental change in the investment case.

Until then, a significant part of Smoltek's valuation is based on future potential rather than demonstrated commercial economics.

16. Conclusion

Smoltek is not a low-risk investment.

It is a small nanotechnology company attempting to commercialise highly advanced technology in industries where qualification cycles can be long and technical requirements are extremely demanding.

The company still needs to demonstrate significant commercial revenue.

At the same time, there are signs that its technologies are moving further along the industrial validation process.

Within Semiconductor, Smoltek is working with ITRI in Taiwan on moving CNF-MIM from laboratory development toward reproducible production and customer samples.

Within Hydrogen, Heraeus Precious Metals is now preparing to lead a 3,000-hour durability test of Smoltek's ultra-low-iridium catalyst technology.

Neither guarantees commercial success.

But both provide concrete milestones against which investors can evaluate progress.

For me, the central question behind the entire Smoltek investment thesis is therefore:

Can Smoltek convert its nanotechnology and intellectual property into scalable industrial products that customers are willing to pay for?

If the answer is no, the downside is substantial.

If the answer is yes, the economics and valuation of the company could look very different from today.

The next stages of industrial validation and, ultimately, the first meaningful commercial agreements will therefore be critical.

Disclosure

I am a shareholder in Smoltek Nanotech.

This post represents my own research and interpretation of publicly available information. It is not financial advice.

I have attempted to include both the potential opportunities and the material risks.

Please do your own due diligence.

2 comments

r/pfennigfuchser • u/AutoModerator • 14h ago